hCCR8(BALB/c)(2)
Nomenclature
BALB/cAnSmoc-Ccr8em(hCCR8)Smoc
Cat. NO.
NM-HU-220501
Strain State
Embryo cryopreservation
Model Description
Validation Data
Fig1. Detection of hCCR8 expression on spleen-derived activated T cells and Tregs in hCCR8 KI mice.
*Splenocytes were activated by anti-mCD3/CD28 antibody in vivo.
Fig2. In vivo antitumor responses of anti-hCCR8 alone in BALB/c hCCR8(v2) knockin mice engrafted with CT26 tumor.
(A) Mean tumor growth curves upon treatment; (B) In vivo antitumor response of anti-hCCR8 in hCCR8 (v2) mice bearing CT26 tumor; (C) Expression of hCCR8 in spleen in hCCR8 (v2) mice bearing CT26 tumor.
Fig3. In vivo antitumor responses of anti-hCCR8 alone or in combination with anti-CTLA-4 in BALB/c hCCR8(v2) knockin mice engrafted with CT26 tumor.
(A) Mean tumor growth curves upon treatment; (B) Individual tumor growth curves upon treatment; (C) In vivo antitumor response of anti-hCCR8 in hCCR8 (v2) mice bearing CT26 tumor.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
